Algernon Pharmaceuticals Inc (AGNPF)

[medchem]

Yes, it doesn't matter whether the patients get really sick and develop acute lung injury and acute respiratory distress syndrome at first, or later after a re-activation occurs. The fact is that data is emerging that shows our body isn't developing a good immune response and that's concerning. Ifenprodil doesn't care about the immune response though. Ifenprodil is an NMDA-antagonist. It plays a role in decreasing the amount of neuron (nerves) hyper-excitability, it also modulates the pulmonary (lung) capillary (small blood vessel) ability to leak out protein and fluid (the stuff that causes the acute respiratory distress syndrome). As I mentioned, that leaking can happen during the initial period of infection or later after re-activation. Ifenprodil will be helpful at either time point.